science-product-detail
DOI: https://doi.org/10.1016/j.fertnstert.2020.05.022
Shortcomings of an unphysiological triggering of oocyte maturation using human chorionic gonadotropin
Claus Yding Andersen, D.M.Sc.a,b, Thomas Kelsey, Ph.D.c, Linn Salto Mamsen, Ph.D.a, and Lan Ngoc Vuong, M.D., Ph.D.d,e,f
Final maturation of follicles has, in connection with ovarian stimulation and infertility treatment, traditionally been achieved by the administration of a human chorionic gonadotropin (hCG) bolus trigger of 5,000 to 10,000 IU. This trigger serves two purposes: induce oocyte maturation; and serve as luteal phase support owing to its long half-life. It now appears that the hCG bolus trigger is unable to support both these two purposes optimally. In particular, after an hCG trigger, the early luteal phase is hormonally abnormal and different from conditions observed in the natural menstrual cycle: the timing of the initiation of hCG and progesterone rise is much faster after an hCG trigger than in a natural menstrual cycle; the maximal concentrations of hCG and progesterone considerably exceed those naturally observed; and the timing of the peak progesterone concentration after an hCG trigger is advanced several days compared with the natural cycle. Furthermore, the hCG trigger without any follicle-stimulating hormone activity may induce oocyte maturation less efficiently than the combined luteinizing hormone and follicle-stimulating hormone surge normally seen. Collectively, the endometrium is likely to be advanced after an hCG trigger, and the implantation potential is probably not optimal. The precise effect on pregnancy rates after the different progressions of hCG and progesterone concentrations during the early luteal phase has not yet been determined, but more individualized methods using more physiological approaches are likely to improve reproductive outcomes.
KEYWORDS:
Early luteal phase, early progesterone rise, endometrial advancement, hCG trigger
Download
Similar articles
-
Review A cost-effectiveness analysis of freeze only or fresh embryo transfer in IVF of non-PCOS women
[ Le KD1, Vuong LN1,2, Ho TM1, Dang VQ1, Pham TD1, Pham CT3, Norman RJ4,5, Mol BWJ6. ]
STUDY QUESTION
Is a freeze-only strategy more cost-effective from a patient perspective than fresh embryo transfe... -
Review COVID-19 and assisted reproductive technology services: repercussions for patients and proposal for individualized clinical management
[ Carlo Alviggi1*, Sandro C. Esteves2,3,4*, Raoul Orvieto5,6, Alessandro Conforti1, Antonio La Marca7, Robert Fischer8, Claus Y. Andersen9, Klaus Bühler10,11, Sesh K. Sunkara12, Nikolaos P. Polyzos13, Ida Strina1, Luigi Carbone1, Fabiola C. Bento2, Daniela Galliano14, Hakan Yarali15, Lan N. Vuong16,17, Michael Grynberg18, Panagiotis Drakopoulos19,20, Pedro Xavier21, Joaquin Llacer22, Fernando Neuspiller23, Marcos Horton24, Matheus Roque25, Evangelos Papanikolaou26,27, Manish Banker28, Michael H. Dahan29, Shu Foong30,31, Herman Tournaye19, Christophe Blockeel 19, Alberto Vaiarelli32, Peter Humaidan4,33, Filippo M. Ubaldi32 and on behalf of the POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) group. ]
Abstract
The prolonged lockdown of health services providing high-complexity fertility trea...
-
Review Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients
[ Sandro C Esteves1, Hakan Yarali2,3, Lan N Vuong4,5,6, José F Carvalho7, İrem Y Özbek2, Mehtap Polat2, Ho L Le4,5, Toan D Pham4,5, Tuong M Ho4,5 ]
STUDY QUESTION
-
Review Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients
[ Sandro C. Esteves1*, Hakan Yarali2,3, Lan N. Vuong4,5,6, José F. Carvalho7, İrem Y. Özbek2, Mehtap Polat2, Ho L. Le4,5, Toan D. Pham4,5, and Tuong M. Ho4,5 on behalf of The POSEIDON Group †
]
Objective: To estimate the prevalence of low-prognosis patients according to the POSEIDON criteria using real-world data.
...https://doi.org/10.3389/fendo.2021.630550
-
Review Endocrine requirements for oocyte maturation following hCG, GnRH agonist, and Kisspeptin during IVF treatment
[ Ali Abbara 1, Tia Hunjan 1, Vu N. A. Ho 2, Sophie A. Clarke 1, Alexander N. Comninos 1, Chioma Izzi-Engbeaya 1, Tuong M. Ho 2, Geoffrey H. Trew 3, Artsiom Hramyka 4, Tom Kelsey 4, Rehan Salim 3, Peter Humaidan 5, Lan N. Vuong 2,6 and Waljit S. Dhillo 1 ]
Objective: The maturation of oocytes to acq...